J Johnson & Johnson
| Market Cap | $585.70B |
| P/E Ratio | 22.03 |
| Forward P/E | 19.33 |
| Dividend Yield | 2.14% |
| Beta | 0.33 |
| 52W Range | $142.39 - $248.56 |
| # Hedge Funds | 14 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Hedge Fund Ownership
| Investor 14 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Tweedy Browne Co. Tweedy Browne Co LLC | 3.94% | $48.85M | 236,075 | Reduce 2.45% |
| Yacktman Asset Management Yacktman Asset Management | 3.63% | $259.24M | 1,252,646 | Reduce 2.69% |
| Mairs & Power Growth Fund Mairs & Power Inc | 1.60% | $166.46M | 804,346 | Reduce 18.38% |
| Robert Olstein Olstein Capital Management | 1.38% | $6.00K | 29,000 | Reduce 40.21% |
| Thomas Gayner Markel Group | 1.01% | $126.40M | 610,800 | — |
| Prem Watsa Fairfax Financial Holdings | 0.73% | $15.19M | 73,400 | — |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.60% | $18.50M | 89,409 | Add 4.97% |
| Richard Pzena Pzena Investment Management | 0.15% | $50.90M | 245,951 | Reduce 0.93% |
| Torray Funds Torray Investment Partners | 0.13% | $873.00K | 4,221 | — |
| Charles Bobrinskoy Ariel Investments | 0.10% | $8.95M | 43,260 | Reduce 16.57% |
| David Katz Matrix Asset Advisors | 0.06% | $642.00K | 3,106 | Reduce 0.16% |
| Jensen Investment Management Jensen Investment Management | 0.03% | $2.12M | 10,266 | Reduce 64.56% |
| Dodge & Cox Dodge & Cox | 0.00% | $4.33M | 20,947 | — |
| Thomas Russo Gardner Russo & Quinn | 0.00% | $201.00K | 976 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 20 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Decker Robert JVP Corporate Controller | Sale | 4,075 | $247.87 | $1.01M | 27 Feb 2026 | 03 Mar 2026 |
| Schmid TimothyEVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324.76K | 20 Feb 2026 | 23 Feb 2026 |
| Schmid TimothyEVP, WW Chair, MedTech | Sale | 8,998 | $244.53 | $2.20M | 18 Feb 2026 | 18 Feb 2026 |
| Schmid TimothyEVP, WW Chair, MedTech | Sale | 13,625 | $244.20 | $3.33M | 18 Feb 2026 | 18 Feb 2026 |
| REED JOHN CEVP, Innovative Medicine, R&D | Sale | 21,721 | $243.00 | $5.28M | 17 Feb 2026 | 18 Feb 2026 |
| Broadhurst VanessaEVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.51M | 17 Feb 2026 | 18 Feb 2026 |
| Wolk Joseph JExec VP, CFO | Sale | 33,386 | $242.75 | $8.10M | 17 Feb 2026 | 18 Feb 2026 |
| Wolk Joseph JExec VP, CFO | Sale | 19,241 | $242.99 | $4.68M | 17 Feb 2026 | 18 Feb 2026 |
| REED JOHN CEVP, Innovative Medicine, R&D | Sale | 2,283 | $243.00 | $554.77K | 17 Feb 2026 | 18 Feb 2026 |
| REED JOHN CEVP, Innovative Medicine, R&D | Sale | 29,927 | $243.00 | $7.27M | 17 Feb 2026 | 18 Feb 2026 |
| Swanson James D.EVP, CIO | Sale | 20,521 | $242.70 | $4.98M | 17 Feb 2026 | 18 Feb 2026 |
| Wolk Joseph JExec VP, CFO | Sale | 24,961 | $242.68 | $6.06M | 17 Feb 2026 | 18 Feb 2026 |
| Wolk Joseph JExec VP, CFO | Sale | 12,066 | $242.87 | $2.93M | 17 Feb 2026 | 18 Feb 2026 |
| Swanson James D.EVP, CIO | Sale | 22,191 | $243.71 | $5.41M | 13 Feb 2026 | 18 Feb 2026 |
| Swanson James D.EVP, CIO | Sale | 19,368 | $243.76 | $4.72M | 13 Feb 2026 | 18 Feb 2026 |
| Duato JoaquinCEO and Chairman of the Board | Sale | 48,782 | $221.48 | $10.80M | 26 Jan 2026 | 28 Jan 2026 |
| Duato JoaquinCEO and Chairman of the Board | Sale | 51,218 | $220.99 | $11.32M | 26 Jan 2026 | 28 Jan 2026 |
| MORIKIS JOHN G | Buy | 1,250 | $206.15 | $257.69K | 26 Nov 2025 | 01 Dec 2025 |
| John G MorikisDirector | Buy | 1,250 | $206.15 | $257.69K | 26 Nov 2025 | 01 Dec 2025 |
| REED JOHN CEVP, Innovative Medicine, R&D | Sale | 21,721 | $192.71 | $4.19M | 17 Oct 2025 | 20 Oct 2025 |
Frequently Asked Questions
What is JNJ stock price today?
Johnson & Johnson (JNJ) is currently trading at $243.04. The stock has a 52-week range of $142.39 to $248.56 and a market capitalization of $585.70B.
Is JNJ a good stock to buy in 2026?
Johnson & Johnson has a P/E ratio of 22.0 (forward P/E: 19.3), a dividend yield of 2.14%, and 1-year performance of +56.3%. 14 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling JNJ stock?
There have been 20 insider transactions for JNJ in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has JNJ stock performed over the past year?
Johnson & Johnson (JNJ) has returned +56.3% over the past 12 months. The stock traded between $142.39 and $248.56 during this period, and is currently at $243.04.
Which hedge funds own JNJ (Johnson & Johnson)?
14 tracked hedge funds currently hold JNJ in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is JNJ's market cap and valuation?
Johnson & Johnson (JNJ) has a market capitalization of $585.70B. The trailing P/E ratio is 22.0 and forward P/E is 19.3. The stock is classified in the Healthcare sector.
What is JNJ's revenue and profitability?
Johnson & Johnson reported revenue of $94.19B with net income of $26.80B and a profit margin of 0.28%. The stock has a beta of 0.33.
What sector is JNJ in and who are its biggest institutional holders?
Johnson & Johnson (JNJ) operates in the Healthcare sector. It is held by 14 tracked hedge funds. See the ownership table above for the complete list.